Michael W. Kalb - 02 Jan 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role: Executive Vice President & CFO
Signature: /s/ Michael W. Kalb
Issuer symbol: CPRX
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jan 2025, 17:00:30 UTC
Previous filing: 25 Nov 2024
Next filing: 24 Nov 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CPRX	Common Stock, par value $0.001 per share	Options Exercise		+7,138			7,138	02 Jan 2025	Direct	F1
transaction	CPRX	Common Stock, par value $0.001 per share	Tax liability		-2,941	-41%		4,197	02 Jan 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CPRX	Restricted Stock Units	Options Exercise	$0	-7,138	-1.5%	$0.000000	475,699	02 Jan 2025	Common Stock	7,138		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2	Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3	Derivative securities vest in equal tranches, 1/5th each on January 1, 2025, 2026, 2027, 2028 and 2029.
F4	Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on January 2, 2025.